BioXcel Therapeutics to Highlight Advances in the BXCL501 Program at 2019 Investor Event in New York City May 13, 2019
BioXcel Therapeutics Showcases Data on BXCL701 in Combination with OX40 Agonist in Late-breaking Poster Presentation at AACR Annual Meeting Apr 1, 2019
BioXcel Therapeutics Files Clinical Trial Application for the Development of BXCL701 and Pembrolizumab in Neuroendocrine Prostate Cancer (tNEPC) Mar 25, 2019
BioXcel Therapeutics Announces Late Breaking Data Presentation at AACR 2019 Annual Meeting Mar 11, 2019
